T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
暂无分享,去创建一个
A. Ferrando | M. Tallman | S. Richards | G. Dewald | A. Moorman | H. Lazarus | E. Paietta | J. Rowe | A. Fielding | A. Goldstone | M. Litzow | R. Ketterling | S. Luger | G. Buck | M. Mansour | D. Marks | A. McMillan | M. Litzow
[1] A. Ferrando,et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Dombret,et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. , 2009, Blood.
[3] A. Hall,et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. , 2009, Blood.
[4] Xiaochun Li,et al. Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial. , 2008 .
[5] R. Pieters,et al. Molecular‐genetic insights in paediatric T‐cell acute lymphoblastic leukaemia , 2008, British journal of haematology.
[6] A. Bhandoola,et al. The earliest thymic progenitors for T cells possess myeloid lineage potential , 2008, Nature.
[7] M. Tallman,et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.
[8] C. Bloomfield,et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Szczepański. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? , 2007, Leukemia.
[10] J. Cayuela,et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.
[11] Rajesh Chopra,et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.
[12] M. Kneba,et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.
[13] A. Cherry,et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.
[14] M. Tallman,et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. , 2006, Blood.
[15] A. Mato,et al. Autologous stem cell transplant in ALL: who should we be transplanting in first remission? , 2006, Bone Marrow Transplantation.
[16] E. Thiel,et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.
[17] R. Foà,et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. , 2006, Blood.
[18] M. Tallman,et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. , 2005, Blood.
[19] E. Thiel,et al. Routine immunophenotyping of acute leukemias , 2005, Blut.
[20] M. Béné,et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. , 2004, Blood.
[21] A. Ferrando,et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. , 2004, Blood.
[22] M. Caligiuri,et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia , 2004, The Lancet.
[23] E. Paietta. How to optimize multiparameter flow cytometry for leukaemia/lymphoma diagnosis. , 2003, Best practice & research. Clinical haematology.
[24] Lawrence R. Johnson,et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. , 2003, Archives of pathology & laboratory medicine.
[25] R. Riley,et al. Immunophenotypic analysis of acute lymphocytic leukemia. , 2002, Hematology/oncology clinics of North America.
[26] A Orfao,et al. New methodologic approaches for immunophenotyping acute leukemias. , 2001, Haematologica.
[27] F. Behm,et al. Immunophenotyping of leukemia. , 2000, Journal of immunological methods.
[28] C. Bloomfield,et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. , 1999, Blood.
[29] E. Schiavone,et al. Immunological classification of acute leukemias: comments on the EGIL proposals. , 1996, Leukemia.
[30] P. Wiernik,et al. Neoplastic Diseases of the Blood , 1991 .
[31] L. Secker-Walker,et al. Evaluation of cytogenetic samples and pertinent technical variables in adult acute lymphocytic leukemia. , 1991, Cancer genetics and cytogenetics.